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Abstract
Enterococci are a major cause of nosocomial bacteraemia. The impacts of vanB vancomycin resistance and antibiotic therapy on outcomes in
enterococcal bacteraemia are unclear. Factors that affect length of stay (LOS) and costs of managing patients with enterococcal bacteraemia are
also unknown. This study aimed to identify factors associated with mortality, LOS and hospitalization costs in patients with enterococcal
bacteraemia and the impact of vancomycin resistance and antibiotic therapy on these outcomes.Data from116 patientswith vancomycin-resistant
Enterococci (VRE), matched 1:1 with patients with vancomycin-susceptible Enterococcus (VSE), from two Australian hospitals were reviewed for
clinical and economic outcomes. Univariable andmultivariable logistic and quantile regression analyses identiﬁed factors associatedwithmortality,
LOS and costs. Intensive care unit admission (OR, 8.57; 95%CI, 3.99–18.38), a higher burdenof co-morbidities (OR, 4.55; 95%CI, 1.83–11.33) and
longer time to appropriate antibiotics (OR, 1.02; 95%CI, 1.01–1.03)were signiﬁcantly associatedwithmortality in enterococcal bacteraemia. VanB
vancomycin resistance increased LOS (4.89 days; 95% CI, 0.56–11.52) and hospitalization costs (AU$ 28 872; 95% CI, 734–70 667), after
adjustment for confounders. Notably, linezolid deﬁnitive therapy was associated with lower mortality (OR, 0.13; 95% CI, 0.03–0.58) in vanB VRE
bacteraemia patients. In patientswithVSEbacteraemia, time to appropriate antibiotics independently inﬂuencedmortality, LOS and hospitalization
costs, and underlying co-morbidities were associated with mortality. The study ﬁndings highlight the importance of preventing VRE bacteraemia
and the signiﬁcance of time to appropriate antibiotics in the management of enterococcal bacteraemia.
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Introduction
In recent years,Enterococcihavebecomeoneof themost common
causes of nosocomial bloodstream infections. Coupled with
the rise in enterococcal infections, is the emergence of
vancomycin-resistant Enterococci (VRE) [1]. The predominant
VRE genotype in published studies is vanA [2]. In Australia, the
majority of isolates are vanB (VRE in Australia: results of the
Australian Group on Antimicrobial Resistance (AGAR) surveys
1995–2010, http://www.agargroup.org/ﬁles/VRE%20in%20Aus-
tralia.pdf) [3], which are susceptible to teicoplanin [2]. VRE
bacteraemia has been linked to increased mortality, prolonged
length of stay (LOS) and higher costs of hospitalization [4,5].
Importantly, the impact of the time to, and type of, antibiotic
therapy on mortality in enterococcal (i.e. VRE and vancomycin-
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susceptible Enterococci (VSE)) bacteraemia is still unclear. Knowl-
edge regarding factors affecting LOS and costs is also lacking.
Identiﬁcation of potentially preventable risk factors for
mortality, LOS and costs of hospitalization, and understanding
the impact of antimicrobial therapy on these outcomes, would
improve the management of patients with enterococcal
bacteraemia. Information regarding the LOS and costs of
hospitalization would also facilitate evaluations of various
infection control measures to minimize the spread of VRE.
Thus, the aims of this study are two-fold: (i) to determine the
factors associated with mortality, LOS and costs in patients
with enterococcal (VRE and VSE) bacteraemia, and (ii) to
investigate the impact of vancomycin resistance and antibiotic
therapy on mortality, LOS and costs in patients with entero-
coccal bacteraemia.
Methods
A retrospective matched cohort study was conducted at two
tertiary hospitals, The Alfred and Austin Health, both in
Victoria, Australia. All inpatients for whom VRE was ﬁrst
isolated from the blood between January 2002 and March 2010
(inclusive) were classiﬁed as VRE patients. Identiﬁcation of
Enterococci was based on VITEK 2 Compact (bio Merioux,
Durham, NC, USA) at The Alfred or D-Ala-D-Ala ligase
polymerase chain reaction (PCR) at Austin Health. Determina-
tion of resistance genotype was based on van gene PCR at both
institutions, which had VRE active screening programmes that
changed over time. Corresponding patients from the same
institutions who had VSE isolated from blood were matched 1:1
with VRE patients according to date of admission (within
2 years) and unit of admission. Where more than one VSE
patient was eligible for matching, the VSE patient was randomly
chosen (without prior knowledge of patient outcomes) from the
list of eligible patients. Patients with LOS >2 days were eligible
for inclusion in the study. Pregnant patients and those <18 years
of age were excluded; these exclusions were to ensure that the
cohort of patients studied was uniform in terms of their
management and treatment considerations for enterococcal
bacteraemia. Risk factors for the development of enterococcal
bacteraemia are presented in another manuscript (Cheah et al.
Case-case–control study on risk factors for development of
vancomycin-resistant and vancomycin-susceptible enterococcal
bacteraemia, manuscript submitted for review).
Information on patient demographics, antimicrobial use,
medical procedures, treatment of enterococcal bacteraemia
and outcomes of hospitalization was collected via a retro-
spective review of patient medical records by the same
researcher (ALYC). All data for costs of hospitalization were
obtained from the clinical costing units of the respective study
hospitals. Costs were in Australian dollars (AU$) and inﬂated
to the ﬁnancial year 2010–2011. Due to the acute nature of
the infection, discounting was not performed. This study was
approved by the Human Research Ethics Committees of The
Alfred Hospital, Austin Health and Monash University.
Deﬁnitions
Deﬁnitions of enterococcal bacteraemia were based upon the
deﬁnitions for nosocomial infections of the Centers for
Disease Control and Prevention (CDC) [6]. Patients with
enterococcal bacteraemia included patients classiﬁed as having
healthcare- or community-associated bacteraemia. Enterococ-
cal bacteraemia was considered to be healthcare-associated if
any one of the following criteria applied [7,8]: (i)  1 positive
blood culture(s) taken more than 48 h after hospital admis-
sion; (ii) patient resided in a nursing home or long-term care
facility, within the last year preceding the positive blood
culture(s); (iii) patient had previous hospital admission for
 2 days, within the last year preceding the positive blood
culture(s); (iv) patient attended hospital for the haemodialysis
clinic or was receiving haemodialysis; or (v) patient received
intravenous therapy at home. Criteria for community-associ-
ated enterococcal bacteraemia were: (i) patient did not meet
the aforementioned criteria for healthcare-associated entero-
coccal bacteraemia, and (ii) patient had  1 positive blood
culture(s) taken  48 h after hospital admission [8].
The Charlson Co-morbidity Index (CCI) was used to
measure co-morbidities [9]. Severity of illness on the day of
positive blood culture was recorded as the Pitt bacteraemia
and Apache II scores [10,11]. Polymicrobial bacteraemia was
the isolation of one or more bacterial or fungal pathogens
within 24 h from the same blood sample that the initial VRE or
VSE was isolated from or a different blood sample. Neutro-
penia days was the number of days neutrophils were <500/
mm3, within 30 days prior to bacteraemia. Exposures to
central lines, mechanical ventilation, urinary catheter and total
parenteral nutrition were deﬁned as exposures within the
30 days prior to bacteraemia. The antibiotic-speciﬁc days were
calculated as the total number of days that antibiotic(s) were
administered orally or intravenously, within 30 days prior to
bacteraemia. Deﬁnitive therapy referred to antibiotic(s)
administered to the patient upon receipt of ﬁnal culture and
susceptibility results. ‘Days to appropriate antibiotics’ was
deﬁned as the number of days before antibiotics to which the
Enterococci isolated were susceptible were administered.
Data analyses
Comparisons were performed for matched VRE and VSE
patients (Table 1). Continuous variables were ﬁrst tested for
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skew. Depending upon whether data were skewed or normally
distributed, Wilcoxon matched-pairs signed rank or matched-
pairs t-tests were used, respectively. Categorical variables
were compared using the McNemar test [12].
Regression analyses were performed for patients with entero-
coccal (VRE and VSE) bacteraemia, and individual VRE and VSE
bacteraemia groups. Variables previously identiﬁed in the litera-
ture, or clinically important or biologically plausible factors, were
included in multivariable models. The variables related to
appropriateness of antibiotic therapy and ‘VRE bacteraemia’
(independent variablesof interest), ‘total numberof intensive care
unit (ICU) admissions’ and/or ‘prior ICU stay’ were included in all
multivariablemodels. All models for LOS and costs were adjusted
for in-patient mortality and duration of hospitalization prior to
bacteraemia. Adjustment for the variables ‘enterococcal species’
and ‘healthcare-associated bacteraemia’ was performed
wherever possible (dependent on assessments of model ﬁt).
The CCI with various cut-offs of 2, 3 or 4 was used to measure
patient co-morbidities. TheCCI variablewith the smallest p-value
was included in the multivariable models.
Logistic regression was used to identify factors associated
with in-hospital mortality in the individual VRE and VSE groups.
In the analysis involving enterococcal bacteraemia patients,
matching was accounted for via the cluster option. As LOS and
cost outcomes were highly skewed, resistant to transforma-
tion and had heteroskedastic residuals with linear regression,
quantile (median) regression was used. Censored least abso-
lute deviations estimator quantile regression (CLAD)
TABLE 1. Comparison of demographics, clinical characteristics and outcomes of patients with enterococcal bacteraemia
Characteristics
VRE bacteraemia,
n = 116
VSE bacteraemia,
n = 116 p-values
Age, median (IQR), years 60 (47–68) 63.5 (51–76) 0.095
Female 47 (41) 44 (38) 0.691
Transfer from another hospital 28 (24) 21 (18) 0.237
Reason for admission
Medical 89 (77) 87 (75) Reference
Surgical 27 (23) 29 (25) 0.670
Charlson Co-morbidity Index, median (IQR) 4 (2–5) 3 (1–5) 0.507
Charlson Co-morbidity Index  2 92 (79) 84 (72) 0.194
Charlson Co-morbidity Index  3 84 (72) 70 (60) 0.048
Charlson Co-morbidity Index  4 73 (63) 57 (49) 0.024
ICU admission in prior 30 days 39 (34) 29 (25) 0.423
Total number of ICU admissions, median (IQR) 0 (0–1) 0 (0–1) 0.228
Neutropenia days, median (IQR), days 1 (0–10) 0 <0.001
Liver disease 16 (14) 13 (11) 0.467
Central line use 94 (81) 59 (51) <0.001
Mechanical ventilation 29 (25) 17 (15) 0.034
Urinary catheter 57 (49) 46 (40) 0.138
Parenteral nutrition 28 (24) 16 (14) 0.040
Prior antibiotic therapy 110 (95) 80 (69) <0.001
Third generation cephalosporin (cefotaxime, ceftriaxone and ceftazidime), mean (SD), days 1.4 (3.2) 1.4 (2.9) 0.950
Fluoroquinolone (moxiﬂoxacin, norﬂoxacin and ciproﬂoxacin), mean (SD), days 4.7 (6.7) 1.9 (4.1) <0.001
Metronidazole, mean (SD), days 2.1 (4.4) 1.9 (4.5) 0.754
Ticarcillin-clavulanic acid, mean (SD), days 7.2 (68.9) 0.7 (2.7) 0.901
Piperacillin-tazobactam, mean (SD), days 1.6 (3.2) 0.5 (2.1) <0.001
Meropenem, mean (SD), days 3.9 (6.3) 1.4 (4.0) <0.001
Vancomycin, mean (SD), days 5.0 (6.2) 2.0 (4.2) <0.001
Any infection (other than enterococcal bacteraemia) 61 (53) 43 (37) 0.537
Number of sets of positive cultures, median (IQR) 1 (1–3) 1 (1–2) 0.008
Sets of positive cultures  2 56 (48) 43 (37) 0.096
Pitt bacteraemia score, median (IQR) 1 (0–3) 1 (0–2) 0.364
APACHE II score, median (IQR) 17 (13–21) 15 (11–20) 0.005
Enterococci species
E. faecalis 9 (8) 71 (61) Reference
E. faecium 107 (92) 39 (34) <0.001
E. casseliﬂavus, E. galinarum or E. durans – 4 (3) –
Both E. faecalis and E. faecium – 1 (1) –
Unknown species – 1 (1) –
Polymicrobial bacteraemia 33 (28) 53 (46) 0.024
Admission days till bacteraemia, median (IQR), days 16 (7–24) 7.5 (1–18.5) 0.003
Admission days after initial culture, median (IQR), days 18 (8–29.5) 15 (10–24.5) 0.599
In-hospital mortality 42 (36) 30 (26) 0.077
Total length of stay, median (IQR), days 35 (22.5–50.5) 25 (16–45.5) 0.103
Total costs, median (IQR), AU$ 86 540 (47 436–170 706) 43 178 (27 578–100 177) 0.002
Allied health 2263 (1396–3650) 1205 (545–2809)
Emergency 0 (0–682) 550 (0–1293)
ICU 0 (0–38 946) 0 (0–10 596)
Medical surgical 0 (0–3193) 0 (0–507)
Medical non-surgical 4909 (1476–10 539) 4353 (1842–8798)
Nursing 19 005 (7066–30 157) 11 854 (5037–20 543)
Pathology 6935 (2426–10 767) 2966 (1497–7258)
Imaging 4175 (2099–6810) 2027 (786–3951)
Pharmacy 20 607 (5676–54 881) 3813 (1136–14 023)
Theatre operating room 373 (0–5253) 143 (0–3115)
Theatre non-operating room 236 (99–1469) 131 (0–909)
Data are number (%) of patients unless indicated otherwise.
Percentages were rounded to the nearest whole number.
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accounted for matching (in the analysis for enterococcal
bacteraemia patients) and heteroscedasticity [13]. The ﬁts of
the multivariable logistic regression models were assessed
using the Hosmer-Lemeshow Goodness-of-Fit test. The link-
test [14] was utilized to assess model speciﬁcation error in the
multivariable quantile regression and CLAD models.
Statistical tests were two-tailed and a p <0.05 was
considered signiﬁcant. All analyses were performed with Stata
version 12.0 (Stata Corporation, College Station, TX, USA).
Results
From January 2002 to March 2010, of 724 patients with
enterococcal bacteraemia across the two clinical sites, there
were 121 (17%) and 603 (83%) patientswith positive VRE andVSE
blood isolates, respectively. A ﬁnal number of 116 VRE bacter-
aemia patients were included in the analysis as four patients had
missing medical records and one patient was pregnant; 116
matching VSE bacteraemia patients were randomly selected from
the 603 above. As the majority of VRE patients were admitted
from 2008 to 2010, matching VRE and VSE patients for date of
admission minimized any impact of variations in infection control
and medical management over the study period.
All VRE isolates were vanB genotype. Vancomycin mini-
mum inhibitory concentrations were determined for only
approximately 37% of isolates; thus, data have not been
included. Demographics, clinical characteristics and out-
comes of patients with enterococcal bacteraemia are shown
in Table 1. For the studied admission, the reasons for
admission and co-morbidities were similar across the VRE
and VSE groups of patients.
In the VRE patients, 54 (47%), 22 (19%) and 14 (12%) were
treated with teicoplanin monotherapy, linezolid monotherapy
or nil antibiotics, respectively. For patients treated with
teicoplanin, loading doses of 400–800 mg (6–12 mg/kg)
12-hourly for three doses, then maintenance doses of 400–
800 mg daily were administered intravenously, with adjust-
ments for renal impairment. Teicoplanin doses of 800 mg daily
without loading doses were administered to three (0.06%)
patients. The linezolid dose was 600 mg twice daily via
intravenous (IV) injection or orally. A combination (concurrent
or in sequence) of teicoplanin, linezolid, quinupristin-dalfopri-
stin or benzylpenicillin as deﬁnitive therapy was administered
to 26 (22%) patients with VRE.
In the VSE patients, deﬁnitive therapy with IV glycopeptides
(12-hourly vancomycin 1 g or teicoplanin 400–800 mg), peni-
cillins (ampicillin 1–2 g 4- to 6-hourly, benzylpenicillin 1.8 g 4-
hourly, ticarcillin-clavulanic acid 3 g/0.1 g 4 to 6-hourly or
piperacillin-tazobactam 4/0.5 g 8-hourly), meropenem 500 mg
8-hourly and no antibiotics were given to 46 (40%), 21 (18%),
one (1%) and nine (8%) patients, respectively. A combination
(concurrent or in sequence) of vancomycin, teicoplanin, linezo-
lid, ampicillin, benzylpenicillin or meropenem was administered
to 30 (26%) of the VSE patients. Intravenous gentamicin 90–
240 mg daily was administered in combination with ampicillin in
six (5%) patients with VSE. In two (2%) patients with VSE, oral
linezolid 600 mg twice daily was administered.
Factors associated with mortality in patients with entero-
coccal (i.e. both VRE and VSE), VRE-only and VSE-only
TABLE 2. Factors associated with in-hospital mortality among patients with enterococcal bacteraemia (clustered logistic
regression)
Variable
Patients who
died, n = 72
Patients who
survived, n = 160
Univariable Multivariable
OR 95% CI OR 95% CI
Age, median (IQR), years 61 (51.5–69.5) 62 (47–73) 1.00 0.98–1.02
Female 25 (35) 66 (41) 0.76 0.42–1.37
Healthcare-associated bacteraemia 40 (56) 88 (55) 1.02 0.59–1.77 0.96 0.46–2.01
Prior ICU stay 51 (71) 47 (29) 5.84 3.13–10.91 8.57 3.99–18.38
Charlson Co-morbidity Index  2 57 (79) 119 (74) 1.31 0.66–2.60
Charlson Co-morbidity Index  3 54 (75) 100 (62.5) 1.80 0.94–3.44 4.55 1.83–11.33
Charlson Co-morbidity Index  4 46 (64) 84 (52.5) 1.60 0.94–2.72
Pitt bacteraemia score, median (IQR) 2 (1–3) 1 (0–2) 1.48 1.21–1.81
Apache II score, median (IQR) 18 (15–23) 15 (11–19) 1.10 1.05–1.16
Neutropenia days 0 (0–5) 0 (0–6.5) 1.00 0.97–1.03
Any infection (other than enterococcal bacteraemia) 61 (85) 117 (73) 2.04 1.02–4.06 1.31 0.49–3.49
VRE bacteraemia 42 (58) 74 (46) 1.63 0.95–2.79 1.21 0.53–2.79
Polymicrobial bacteraemia 24 (33) 59 (37) 0.86 0.47–1.54
Number of sets of positive culture, median (IQR) 1 (1–3) 1 (1–2) 1.15 1.03–1.28
Enterococci species
E. faecalis 17 (24) 63 (39) Reference Reference
E. faecium 52 (72) 94 (59) 2.05 1.12–3.75 1.12 0.42–3.01
E. casseliﬂavus, E. galinarum or E. durans 1 (1) 3 (2) 1.24 0.12–13.13 1.79 0.32–9.96
Both E. faecalis and E. faecium 1 (1) 0 – – – –
Unknown 1 (1) 0 – – – –
Days to appropriate antibiotic, median (IQR), days 1.5 (0.7–2.6) 1.6 (0.8–2.9) 1.01 1.00–1.02 1.02 1.01–1.03
Appropriate antibiotics in 24 h 15 (21) 26 (16) 1.68 0.79–3.55
Appropriate antibiotics in 48 h 37 (51) 86 (54) 1.35 0.70–2.61
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bacteraemia are presented in Tables 2 and 3. Tables 4 and 5
list the factors associated with LOS and costs.
Notably, VRE bacteraemia was not associated with increased
mortality in patients with enterococcal bacteraemia (Table 2),
but VRE bacteraemia was independently associated with
prolonged LOS and higher hospitalization costs (Table 4).
For patients with VRE bacteraemia (Table 3), prior ICU
admission, CCI  4 and nil deﬁnitive antibiotic therapy were
associated with mortality. Linezolid therapy in patients with
VRE bacteraemia was associated with reduced mortality. LOS
and costs in patients with VRE bacteraemia were not
inﬂuenced by type of antibiotic therapy (Table 5).
In patients with VSE bacteraemia, an increase in the number
of days to appropriate antibiotics was associated with higher
odds of mortality (Table 3), longer LOS and higher costs
(Table 5).
Discussion
To our knowledge, this is the ﬁrst study to investigate the
outcomes of vanB VRE bacteraemia patients treated with teicopl-
anin. It is also the ﬁrst to estimate the LOS and costs of
hospitalization for enterococcal bacteraemia in the Australian
hospital setting. The strength of this study is that corresponding
mortality, LOS and costs data for patients with enterococcal
bacteraemia were compared. As such, the impact of vanB
vancomycin resistanceonmortality, LOSand costswas elucidated.
In contrast to results of previous studies on factors
associated with mortality in vanA VRE bacteraemia (summa-
rized in a meta-analysis) [15], our study ﬁndings suggest that
vanB VRE bacteraemia was not associated with mortality after
adjusting for co-morbidities, prior ICU admission and days to
appropriate antibiotic therapy. The meta-analysis revealed that
vanA vancomycin resistance (i.e. VRE infections) more than
doubled the odds of death in enterococcal infections [15]. It is
possible that the effect of vancomycin resistance may have been
confounded in the meta-analysis by inappropriate or inadequate
antimicrobial therapy. Earlier studies predominantly included
vanA isolates and involved only a small proportion of patients
treated with antibiotics that were active against VRE (e.g. under
compassionate-use programmes) or older agents such as
chloramphenicol and quinupristin-dalfopristin [16–18]. A
recent study that could not adjust for appropriate antibiotic
therapy found that VRE bacteraemia was linked to higher
mortality 1 year after haematopoietic stem cell transplantation
[19]. In contrast, in the present study, adjustment was made for
time to appropriate antibiotic therapy in the analysis. Thus, the
impact of vancomycin resistance on mortality is probably less
profound and may partially explain our ﬁndings.T
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An increase in the time to appropriate antibiotic therapy
was independently associated with higher odds of in-hospital
mortality in patients with enterococcal bacteraemia. This
ﬁnding was supported by results from another study, wherein
appropriate antibiotics within 48 h of positive blood culture
were found to independently reduce the odds of death in
enterococcal bacteraemia [16]. Importantly, the results from
the current study suggest that compared with teicoplanin,
linezolid therapy for vanB VRE bacteraemia was associated
with lower odds of in-hospital mortality. Comparison with
ﬁndings from earlier studies is difﬁcult given that the vanA
genotype was predominant in the earlier studies, and ﬁndings
from those studies are varied [17, 20–24]. For example,
Camins et al. found that appropriate administration of antibi-
otics (chloramphenicol and quinupristin-dalfopristin) was
linked to lower mortality in VRE bacteraemia [17]. In another
study, daptomycin trended towards higher mortality when
compared with linezolid [24]. Conversely, other studies
reported that linezolid vs. quinupristin-dalfopristin [20,21], or
linezolid vs. daptomycin [22, 23, 25], did not have an impact on
mortality in VRE bacteraemia. In the present study, the type of
antibiotic (for VRE only) and time to appropriate antibiotic (for
VSE only) independently inﬂuenced mortality. The latter
observation was supported by a recent study which found
that inappropriate antibiotic therapy in VSE bacteraemia
independently increased the odds of mortality [26].
Patient co-morbidities signiﬁcantly inﬂuenced mortality in
enterococcal bacteraemia. Prior ICU stay (which may repre-
sent severity of bacteraemia) was also strongly associated with
odds of death in enterococcal and VRE bacteraemia. Published
data suggest that patient co-morbidities and illness severity
were linked to higher mortality in patients with enterococcal
bacteraemia [27–29] and VRE bacteraemia [20,21], respec-
tively. Similar to another study [17], VRE bacteraemia patients
with a CCI  4 had higher odds of death in the present study.
Interestingly, in the current study a higher CCI cut-off was
signiﬁcantly associated with increased odds of death in patients
with VRE compared with VSE bacteraemia.
VanB VRE bacteraemia was found to be independently
associated with longer LOS and higher costs of hospitalization.
This ﬁnding was consistent with a study involving vanA VRE
bacteraemia, which adjusted LOS and costs for illness severity
and ICU admission [4]. Differences in LOS and cost estimates
between the aforementioned [4] and the current study may be
due to differences in VRE genotype, approaches to costing and
healthcare systems, and adjustment for appropriateness of
antibiotic therapy in the analysis of the present study.
Our data suggest that advancing age reduced hospitalization
costs. This may be due to the preference for less aggressive
and possibly less expensive therapy in the elderly. OlderT
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TABLE 5. Factors associated with length of stay and costs of hospitalization among patients with VRE and VSE bacteraemia
(quantile regression)
Variables
Length of stay, days Costs of hospitalization, AU$
Univariable Multivariable Univariable Multivariable
Coefﬁcient 95% CI Coefﬁcient 95% CI Coefﬁcient 95% CI Coefﬁcient 95% CI
VRE bacteraemia
Age 0.13 0.37–0.11 1508 2152 to 863 751 1684–183
Female 1 8.77–6.77 11 488 46 295–23 318
Healthcare-associated
bacteraemia
18 9.31–26.69 68 771 30 905–106 637
ICU stay 0 6.47–6.47 44.46 56.57 to 32.34 64 242 18 893–109 591 136 584 180 095
to 93 072
Total number of ICU
admissions
10 4.30–15.70 44.40 38.70–50.09 99 953 79 942–119 963 154 176 140 038–168 314
Charlson Co-morbidity
Index  2
7 14.83–0.83 1.03 8.42–10.49 21 322 71 864–27 220 21 770 56 898–13 358
Charlson Co-morbidity
Index  3
3 10.29–4.29 2357 40 334–35 620
Charlson Co-morbidity
Index  4
3 9.75–3.75 2 357 34 898–30 184
Any infection
(other than
enterococcal
bacteraemia)
9 2.57–20.57 4.41 3.62–12.43 51 456 15 597–87 316 30 779 1475–63 033
E. faecium compared
with E.
faecalis bacteraemia
12 1.70–25.70 5.47 7.87–18.80 51 323 5260–107 905
Polymicrobial
bacteraemia
0 6.96–6.96 651 37 899–36 597
Sets of positive
cultures  2
10 3.54–16.46 51 725 19 341–84 109
Pitt bacteraemia
score  4
5 15.20–5.20 39 246 18 044–96 536
Days to appropriate
antibiotic
0.87 3.29–1.56 0.64 2.42–1.14 7505 22 743–7732 974 7674–9622
Appropriate antibiotics
in 48 h
1 6.93–8.93 9432 53 112–34 249
Days from admission
until
bacteraemia
1.04 0.83–1.24 1.02 0.84–1.20 3470 2869–4070 1662 921–2402
In-patient mortality 4 10.60–2.60 15.85 24.70 to 7.01 24 499 20 637–69 636 9095 46 549–28 358
Type of deﬁnitive
therapy
Teicoplanin Reference Reference
Linezolid 4 13.58–5.58 6.88 15.80–2.05 51 302 95 641 to 6964 31 120 65 056–2815
Other 4 5.31–13.31 3.64 5.03–12.31 15 359 26 981–57 699 3217 36 937–30 504
Nil antibiotics 10 21.08–1.08 33 448 83 622–16 727
VSE bacteraemia
Age 0.31 0.55 to 0.07 0.05 0.08–0.19 1294 1956 to 633 551 1013 to 89
Female 2 13.05–9.05 9250 37 157–18 657
Healthcare-associated
bacteraemia
17 9.95–24.05 28 824 8162–49 486
Prior ICU stay 9 0.17–17.83 3.24 9.72–3.24 55 759 42 925–68 593 18 370 748–35 991
Total number of ICU
admissions
13 9.23–16.77 7.70 4.08–11.32 48 843 43 040–54 645
Charlson Co-morbidity
Index  2
8 19.91–3.91 0.47 5.95–5.00 47 409 68 451 to 26 367 28 697 47 930–9 464
Charlson Co-morbidity
Index  3
3 15.06–9.06 36 782 56 607 to 16 958
Charlson Co-morbidity
Index  4
2 7.74–11.74 24 501 46 972–2031
Any infection (other than
enterococcal
bacteraemia)
11 0.82–21.18 2.76 2.50–8.01 17 960 9703–45 624 504 18 072–19 081
Enterococci species
E. faecalis Reference Reference Reference
E. faecium 5 6.68–16.68 10 132 17 467–37 730 6385 24 025–11 254
E. casseliﬂavus,
E. galinarum or
E. durans
10 35.61–15.61 17 763 77 437–41 911 7607 37 618–22 403
Both E. faecalis and
E. faecium
2 8.81–4.81 69 824 53 733–85 916 6191 33 286–20 904
Unknown      
Polymicrobial bacteraemia 0 9.82–9.82 7053 24 505–38 612
Sets of positive cultures
 2
7 3.21–17.21 5.36 0.77–9.95 5806 22 124–33 737
Pitt bacteraemia score  4 1 15.85–17.85 88 194 55 833–120 554
Days to appropriate
antibiotic
0.11 0.10–0.13 0.06 0.03–0.08 442 395–489 753 655–851
Appropriate antibiotics in
48 h
4 8.90–16.90 11 697 22 974–46 367
Days from admission
until bacteraemia
1.12 1.01–1.22 0.98 0.83–1.13 2652 2345–2960 1967 1494–2440
In-patient mortality 2 7.70–11.70 7.57 12.99 to 2.15 16 418 8335–41 171 3067 17 060–23 194
ª2013 The Authors
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patients are likely to be sicker and may not be able to tolerate
aggressive treatments such as surgery [30]. We have also
noted that infections other than enterococcal bacteraemia
were independently associated with prolonged LOS. An
increase in the number of ICU admissions per patient was
associated with prolonged LOS, which may be due to a higher
severity of illness. Hence, future studies of this type should
control for other types of infections via adjustment in the
multivariable analysis. In patients with enterococcal bacter-
aemia, a higher burden of patient co-morbidities did not
signiﬁcantly affect LOS and costs of hospitalization, in contrast
to their effect on mortality. The reasons for this are currently
unknown. Future studies could explore the impact and validity
of various measures of co-morbidities on the outcomes of LOS
and costs.
Retrospective data collection and pooling of data may be
subject to variability. To ensure precision in data interpreta-
tion, criteria for the exposure and outcome measures were
standardized prior to study commencement. As the majority
of VRE patients were admitted from 2008 to 2010, matching
VRE and VSE patients for date of admission minimized any
impact of variations in infection control and medical manage-
ment over the study period. Furthermore, standardized data
on costs of hospitalization submitted to the Australian
government for the purpose of hospital funding reimburse-
ment were utilized.
In summary, vanB VRE bacteraemia was independently
associated with increased LOS and costs of hospitalization.
Thus, it is crucial to prevent the spread of VRE, from both
patient care and resource management perspectives. Impor-
tantly, we reveal for the ﬁrst time that linezolid deﬁnitive
therapy, compared with teicoplanin, was associated with lower
odds of mortality. Further investigation via randomized
controlled trials comparing the effectiveness of existing
antibiotics in managing vanB VRE bacteraemia is warranted.
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